Jan. 9 at 4:16 PM
Attached is our updated tracker showing what's happened to the share prices of all 61 new comm'l-stage oncology focused bios receiving 1st FDA approval of a cancer therapy since 1/1/13.
The historical evidence is overwhelming shareholder value is maximized, almost 100% of the time, via M&A exit within 2 years of FDA approval.
$NUVB is the 1 possible outlier (so far) but we'd remind investors it's been 6 months since Ibtrozi's approval. There are many bios in this peer group that showed big gains like NUVB only to fall later on disappointing circumstances (sales &/or clinical data).
$ONC is up 73% since Brukinsa was 1st approved 6+ years ago. We suspect shareholders could have realized even higher gains within 1 year via M&A exit.
There is not 1 bio in this peer group that has delivered meaningful or NASDAQ like gains to shareholders over a sustained period of time going back to 1/1/13.
Shouldn't bios in this peer group exit via M&A?
$DAWN $XFOR $KURA
What are we missing? Please push back
